<i>TMED9</i>Expression Level as a Biomarker of Epithelial Ovarian Cancer Progression and Prognosis

Han, Gwan Hee; Jung, Bock-Young; Chung, Jinwook; Kim, Jae-Hoon; Cho, Hanbyoul

doi:10.21873/cgp.20352

Cited by 5 publications

(4 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A recent study confirmed that high TMED9 expression was correlated to progression, plasma cell type, and inferior histological grade in epithelial ovarian cancer, which demonstrates potential predictive value for both disease-free and overall survival. More in-depth functional studies revealed that TMED9 knockdown decreased epithelial ovarian carcinoma (EOC) cells' migration, invasion, cell proliferation, and colony formation, indicating TMED9 might be a useful prognostic biomarker and supporting the idea that targeting TMED9 might be an innovative approach to treating EOC 61 .…”

Section: Progress Of the Tmed Family In Some Common Human Diseasesmentioning

confidence: 91%

TMED family genes and their roles in human diseases

Zhou,

Li,

Yao

et al. 2023

Int. J. Med. Sci.

View full text Add to dashboard Cite

The members of the transmembrane emp24 domain-containing protein (TMED) family are summarized in human as four subfamilies, α (TMED 4, 9), β (TMED 2), γ (TMED1, 3, 5, 6, 7) and δ (TMED 10), with a total of nine members, which are important regulators of intracellular protein transport and are involved in normal embryonic development, as well as in the pathogenic processes of many human diseases. Here we systematically review the composition, structure and function of TMED family members, and describe the progress of TMED family in human diseases, including malignancies (head and neck tumors, lung cancer, breast cancer, ovarian cancer, endometrial cancer, gastrointestinal tumors, urological tumors, osteosarcomas, etc.), immune responses, diabetes, neurodegenerative diseases, and nonalcoholic fatty liver disease, dilated cardiomyopathy, mucin 1 nephropathy (MKD), and desiccation syndrome (SS). Finally, we discuss and prospect the potential of TMED for disease prognosis prediction and therapeutic targeting, with a view to laying the foundation for therapeutic research based on TMED family causative genes.

show abstract

Section: Progress Of the Tmed Family In Some Common Human Diseasesmentioning

confidence: 91%

TMED family genes and their roles in human diseases

Zhou,

Li,

Yao

et al. 2023

Int. J. Med. Sci.

View full text Add to dashboard Cite

show abstract

“…Similarly, elevated TMED9 expression is associated with reduced survival time in individuals with epithelial ovarian cancer (EOC) in vivo. TMED9 knockdown reduces EOC cell proliferation in vitro ( Han et al, 2022 ).…”

Section: Tmed9 Interactions In Health and Diseasementioning

confidence: 99%

The many hats of transmembrane emp24 domain protein TMED9 in secretory pathway homeostasis

Roberts

Satpute-Krishnan

2023

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

The secretory pathway is an intracellular highway for the vesicular transport of newly synthesized proteins that spans the endoplasmic reticulum (ER), Golgi, lysosomes and the cell surface. A variety of cargo receptors, chaperones, and quality control proteins maintain the smooth flow of cargo along this route. Among these is vesicular transport protein TMED9, which belongs to the p24/transmembrane emp24 domain (TMED) family of proteins, and is expressed across vertebrate species. The TMED family is comprised of structurally-related type I transmembrane proteins with a luminal N-terminal Golgi-dynamics domain, a luminal coiled-coil domain, a transmembrane domain and a short cytosolic C-terminal tail that binds COPI and COPII coat proteins. TMED9, like other members of the TMED family, was first identified as an abundant constituent of the COPI and COPII coated vesicles that mediate traffic between the ER and the Golgi. TMED9 is typically purified in hetero-oligomers together with TMED family members, suggesting that it may function as part of a complex. Recently, TMED family members have been discovered to play various roles in secretory pathway homeostasis including secreted protein processing, quality control and degradation of misfolded proteins, and post-Golgi trafficking. In particular, TMED9 has been implicated in autophagy, lysosomal sorting, viral replication and cancer, which we will discuss in this Mini-Review.

show abstract

“…4A and B, the expressions of 9764 genes were positively correlated with the expression of hnRNPAB, and 10214 genes were negatively correlated with hnRNPAB. Several hnRNPAB-positive correlated genes with high Pearson Correlations that have been reported to be associated with tumorigenesis were screened to perform the co-expression analysis with hnRNPAB using the mRNA expression data of 585 LUAD and 550 LUSC samples obtained from the TCGA database, including NOP16 nucleolar protein (NOP16), nucleophosmin 1 (NPM1), treacle ribosome biogenesis factor 1 (TCOF1), centromere protein H (CENPH), cyclin B1 (CCNB1), heat shock protein family A (Hsp70) member 9 (HSPA9), sideroflexin 1 (SFXN1), protein phosphatase, Mg 2+ /Mn 2+ dependent 1G (PPM1G), transmembrane p24 trafficking protein 9 (TMED9), and DEAD-box helicase 41 (DDX41) (15)(16)(17)(18)(19)(20)(21)(22)(23)(24)(25)(26). As shown in Fig.…”

Section: Analysis Of Genes Related To Hnrnpab Expression In Nsclcmentioning

confidence: 99%

HnRNPAB is an independent prognostic factor in non‑small cell lung cancer and is involved in cell proliferation and metastasis

et al. 2023

View full text Add to dashboard Cite

Heterogeneous nuclear ribonucleoprotein A/B (hnRNPAB) is an RNA binding protein that is closely associated with the biological function and metabolism of RNA, which is involved in the malignant transformation of various tumor cells. However, the role and mechanisms of hnRNPAB in non-small cell lung cancer (NSCLC) are still unclear. In the present study, the expression levels of hnRNPAB in NSCLC and normal tissues were analyzed using the human protein atlas database and UALCAN database. The clinical significance of hnRNPAB was assayed using the data of NSCLC cases from The Cancer Genome Atlas database. Subsequently, two stable NSCLC cell lines with hnRNPAB knockdown were constructed and the effects of hnRNPAB silencing on cell viability, migration, invasion and epithelial-mesenchymal transition (EMT) were identified. Genes associated with hnRNPAB expression in NSCLC were screened using the Linked Omics database and verified by quantitative real-time PCR (RT-qPCR). The database analysis indicated that hnRNPAB was mainly expressed in the nucleus of NSCLC cells. Compared with the normal tissues, hnRNPAB expression was overexpressed in NSCLC tissues and was closely associated with the overall survival, sex, tumor-node-metastases classification, and poor prognosis of patients with lung adenocarcinoma. Functionally, knockdown of hnRNPAB inhibited the proliferation, migration, invasion and EMT of NSCLC cells and arrested the cell cycle at G 1 phase. Mechanistically, the bioinformatics analysis and RT-qPCR verification demonstrated that hnRNPAB knockdown led to a significant expression change of genes associated with tumorigenesis. In conclusion, the present study indicated that hnRNPAB played an important role in the malignant transformation of NSCLC, supporting the significance of hnRNPAB as a novel potential therapeutic target for the early diagnosis and prognosis of NSCLC.

show abstract

TMED9Expression Level as a Biomarker of Epithelial Ovarian Cancer Progression and Prognosis

Cited by 5 publications

References 30 publications

TMED family genes and their roles in human diseases

TMED family genes and their roles in human diseases

The many hats of transmembrane emp24 domain protein TMED9 in secretory pathway homeostasis

HnRNPAB is an independent prognostic factor in non‑small cell lung cancer and is involved in cell proliferation and metastasis

Contact Info

Product

Resources

About